Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Heterocyclic kinase scaffold engineering: MerckRecent Research Landscape

Unregulated signaling in the IRAK and PI3K delta pathways drives chronic inflammatory pathology. These innovations utilize specific heteroaryl and purine scaffolds to competitively inhibit enzyme binding sites and restore immune homeostasis.

What technical problems is Merck addressing in Heterocyclic kinase scaffold engineering?

Inadequate kinase selectivity

(24)evidences

Unregulated signaling through GCN2 and RIPK1 pathways triggers maladaptive cellular stress responses and necroptosis. Preventing these specific biochemical malfunctions mitigates chronic inflammatory and neurodegenerative disease progression.

Insufficient kinase binding selectivity

(6)evidences

Uncontrolled signaling in B-cells and myeloid cells leads to chronic tissue destruction. Mitigating this dysfunction prevents the progression of autoimmune and inflammatory pathologies.